Ten PDUFA dates on FDA’s March agenda

Before the end of the month, FDA has at least 10 target action dates on therapeutics under review, including two siRNA therapies originated by Alnylam. 

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is awaiting a March 23 PDFUA that could expand the label of its transthyretin (TTR)-targeting siRNA therapy, Amvuttra vutrisiran, into the larger indication of TTR amyloidosis with cardiomyopathy (ATTR-CM). Therapy is already approved for ATTR with polyneuropathy. ...